title: Use of intravenous anti-D in patients with refractory and relapsed immune thrombocytopenic purpura.
abstract: OBJECTIVE
  To determine the response to i.v. anti-D and its comparison with splenectomy as second line therapy in refractory and relapsed cases of ITP, in the Aga Khan University Hospital, Karachi.
  
  
  METHODS
  A total of 23 patients with chronic ITP were treated with either anti-D or splenectomy as second line treatment. The patients were assessed for time to achieve a response to second line treatment, duration of response and adverse events.
  
  
  RESULTS
  There were 12 patients in the anti-D group and 11 in the splenectomy group. The mean platelet count at presentation was 9,000/cumm. The mean age was 8.9 years and 13.0 years and the male to female ratio was 1:1 and 1:1.2 in anti-D and splenectomy group respectively. 54.5% of the patient in the anti-D group responded compared to 81.8% in the splenectomy group. Median time to achieve a response was 7 days in the anti-D group and 1 day in the splenectomy group. Mean time to relapse was 87.8 days in the anti-D group and 55.4 days in the splenectomy group. No adverse events were recorded for any of the infusions of anti-D and none of the patients had more than 0.5 gm/dl fall in the hemoglobin level following anti-D infusion.
  
  
  CONCLUSIONS
  It was thus concluded that Anti-D is a relatively safe, convenient and effective therapy for chronic ITP and can be used as a splenectomy sparing agent when treatment is clinically indicated.
authors.affiliation: Department of Pathology, The Aga Khan University, Karachi.
authors.forename: R
authors.initials: R
authors.lastname: Sajid
authors.forename: S N
authors.initials: SN
authors.lastname: Adil
authors.forename: Z
authors.initials: Z
authors.lastname: Fadoo
authors.forename: S
authors.initials: S
authors.lastname: Sabir
authors.forename: M
authors.initials: M
authors.lastname: Khurshid
mesh_terms: D000293:Adolescent; D002648:Child; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007518:Isoantibodies; D008297:Male; D010154:Pakistan; D011696:Purpura, Thrombocytopenic / Q000276:immunology / Q000601:surgery / Q000628:therapy*; D012008:Recurrence; D015203:Reproducibility of Results; D018029:Rho(D) Immune Globulin / Q000627:therapeutic use*; D013156:Splenectomy; D016896:Treatment Outcome
chemical_list: D007518:Isoantibodies; C061961:RHO(D) antibody; D018029:Rho(D) Immune Globulin